cyamemazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
746 3546-03-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cyamemazine
  • ciamatil
  • cianatil
  • cyamemazin
  • cyamepromazine
  • cyamepromezine
phototoxic neuroleptic effects
  • Molecular weight: 323.46
  • Formula: C19H21N3S
  • CLOGP: 4.87
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 30.27
  • ALOGS: -4.05
  • ROTB: 4

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 767.86 45.71 272 4727 58077 46622986
Poisoning deliberate 461.58 45.71 117 4882 7809 46673254
Toxicity to various agents 292.77 45.71 214 4785 211552 46469511
Somnolence 173.33 45.71 139 4860 156382 46524681
Hepatocellular injury 156.69 45.71 72 4927 29450 46651613
Rhabdomyolysis 155.52 45.71 80 4919 41829 46639234
Suicide attempt 148.38 45.71 85 4914 54951 46626112
Altered state of consciousness 136.71 45.71 61 4938 23287 46657776
Extrapyramidal disorder 115.63 45.71 44 4955 11224 46669839
Intentional overdose 113.18 45.71 76 4923 64868 46616195
Hypotension 112.52 45.71 131 4868 232458 46448605
Miosis 109.98 45.71 37 4962 6620 46674443
Bladder dilatation 95.66 45.71 21 4978 742 46680321
Wrong patient received product 92.89 45.71 24 4975 1713 46679350
Urinary retention 85.89 45.71 46 4953 26015 46655048
Tachycardia 68.96 45.71 68 4931 99554 46581509
Asphyxia 66.38 45.71 24 4975 5302 46675761
Neuroleptic malignant syndrome 61.67 45.71 28 4971 11094 46669969
Poisoning 58.50 45.71 29 4970 13965 46667098
Vasoplegia syndrome 57.95 45.71 15 4984 1077 46679986
Cerebral microhaemorrhage 56.93 45.71 10 4989 106 46680957
Drug abuse 56.81 45.71 50 4949 63358 46617705
Pyramidal tract syndrome 52.06 45.71 11 4988 323 46680740
Brain death 51.83 45.71 17 4982 2806 46678257
Overdose 51.68 45.71 59 4940 101920 46579143
Alkalosis hypochloraemic 47.35 45.71 9 4990 152 46680911

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 843.91 37.98 291 4305 40158 29907724
Poisoning deliberate 478.66 37.98 122 4474 5782 29942100
Miosis 229.07 37.98 73 4523 7703 29940179
Somnolence 213.78 37.98 150 4446 96613 29851269
Drug abuse 159.84 37.98 118 4478 81954 29865928
Toxicity to various agents 133.30 37.98 149 4447 177034 29770848
Intentional overdose 129.46 37.98 80 4516 41401 29906481
Asphyxia 100.58 37.98 36 4560 5389 29942493
Hepatocellular injury 99.97 37.98 57 4539 25414 29922468
Altered state of consciousness 90.24 37.98 49 4547 19870 29928012
Extrapyramidal disorder 89.55 37.98 40 4556 10653 29937229
Pneumonia aspiration 86.34 37.98 60 4536 37720 29910162
Hyperthermia 66.54 37.98 32 4564 10067 29937815
Colitis ischaemic 62.76 37.98 26 4570 5760 29942122
Mydriasis 57.96 37.98 25 4571 6118 29941764
Drug dependence 56.19 37.98 37 4559 21258 29926624
Rhabdomyolysis 55.40 37.98 58 4538 63522 29884360
Suicide attempt 54.33 37.98 45 4551 36652 29911230
Respiratory depression 54.02 37.98 29 4567 11474 29936408
Disturbance in attention 50.16 37.98 35 4561 22094 29925788
Depressed level of consciousness 48.68 37.98 43 4553 38179 29909703
Bradypnoea 48.23 37.98 16 4580 1905 29945977
Rheumatoid nodule 46.15 37.98 15 4581 1675 29946207
Bladder dilatation 41.40 37.98 13 4583 1299 29946583

Pharmacologic Action:

SourceCodeDescription
ATC N05AA06 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 2.39 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 3A Ion channel Ki 5.53 PDSP
D(3) dopamine receptor GPCR Ki 8.60 PDSP
D(1A) dopamine receptor GPCR Ki 8.42 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.49 PDSP
D(2) dopamine receptor GPCR Ki 8.24 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 7.89 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.46 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 7.92 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 7.38 PDSP
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.80 IUPHAR
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 7.90 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7.20 IUPHAR
5-hydroxytryptamine receptor 1A GPCR ANTAGONIST Ki 6.30 IUPHAR

External reference:

IDSource
D07307 KEGG_DRUG
C0056643 UMLSCUI
CHEBI:135379 CHEBI
CHEMBL2104153 ChEMBL_ID
DB09000 DRUGBANK_ID
C028457 MESH_SUPPLEMENTAL_RECORD_UI
62865 PUBCHEM_CID
84 IUPHAR_LIGAND_ID
1148 INN_ID
A2JGV5CNU4 UNII
21877 RXNORM
005507 NDDF

Pharmaceutical products:

None